RIEDEL NORBERT G

SEC Form 4 insider trading activity

RIEDEL NORBERT G has filed 4 SEC Form 4 filings (7 transaction rows) across 2 companies, including JAZZ, ETON, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Sep 2, 2026.

On the most recent filing, RIEDEL NORBERT G is listed as Director at Jazz Pharmaceuticals plc. Inside the rolling window, RIEDEL NORBERT G reported no open-market purchases and 1 open-market sale totaling $656K in JAZZ.

Companies traded

Other insiders at JAZZ

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$656K

reported sales (SEC code S)

Companies

2

in the rolling window

Source
JAZZ
RIEDEL NORBERT G
Sale$656KMar 2SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has RIEDEL NORBERT G made?

RIEDEL NORBERT G has filed 4 SEC Form 4 filings (7 transaction rows) across 2 companies, including JAZZ, ETON since 2026.

Which companies does RIEDEL NORBERT G trade?

RIEDEL NORBERT G has filed SEC Form 4 disclosures for 2 companies, including JAZZ, ETON.

When was RIEDEL NORBERT G's most recent SEC Form 4 filing?

RIEDEL NORBERT G's most recent SEC Form 4 filing on Tracefour is dated Sep 2, 2026.

What is RIEDEL NORBERT G's total buy and sell value in the current window?

Inside the rolling retention window, RIEDEL NORBERT G bought $0 and sold $656K based on SEC Form 4 filings.

What was RIEDEL NORBERT G's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 3,415 JAZZ shares on 2026-02-27, worth $656K, per SEC Form 4 filings.